ORIC Pharmaceuticals, Inc.

NASDAQ:ORIC

Biotechnology

Healthcare
$7.65 -0.75%

-$0.07 today

Market cap
$795.08M
Beta
1.06
P/E (TTM)
-6.7
EPS (TTM)
-$1.28
52W Low $7.23High $14.93

Volume 1.39M

Average 1.91M

ORIC Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

ORIC Pharmaceuticals, Inc.NASDAQ: ORIC

Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026

Accumulated OCI turns negative

Q1 FY2026 Accumulated OCI was -$290K, compared with $209K a year earlier.

Context

  • Accumulated OCI amounted to 0.1% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Accumulated OCI increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -238.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$290K-136.9% QoQ
Last fiscal yearDec 2025
$786K+107.4% YoY
Year agoMar 2025
$209K-238.8% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-238.8%——
1 year+107.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
786K USD
Year-over-year change
+107.4%

Accumulated OCI vs competitors

How ORIC compares with its peers on the latest reported figures

  • ORIC's Mar 2026 Accumulated OCI of -$290K is the 8th highest of the 11 companies compared; the peer median is -$13.5K.
  • Its year-over-year change of -238.8% is the 6th highest of 10, against a peer median of -97.9%.
  • Accumulated OCI amounts to 0.1% of total assets for ORIC, versus a peer median of 0.1%.
ORIC Competitors Peer median
Accumulated OCI for ORIC and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VSTMVerastem, Inc.Mar 2026$8.62M +29.8%—3.8%
JANXJanux Therapeutics, Inc.Mar 2026$576K -84.7%—0.1%
TYRATyra Biosciences, Inc.Mar 2026$107K -84.4%—0.0%
SNDXSyndax Pharmaceuticals, Inc.Mar 2026$11K -97.9%—0.0%
NVCTNuvectis Pharma, Inc.Mar 2026$0 ——0.0%
MGNXMacroGenics, Inc.Mar 2026-$27K -2600.0%—0.0%
AVBPArriVent BioPharma, Inc. Common StockMar 2026-$270K -1488.2%—0.1%
ORICORIC Pharmaceuticals, Inc.Mar 2026-$290K -238.8%—0.1%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026-$1.13M +10.2%—0.4%
NUVBNuvation Bio Inc.Jun 2026-$2.61M -698.5%—0.4%
ELVNEnliven Therapeutics, Inc.Sep 2026-$3.51M -1689.6%—0.4%
Peer median (excluding ORIC) -$13.5K-97.9%—0.1%

Competitors are the stored peer set for ORIC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents226.01M66.84M23.38M59.41M45.67M
Short-term Investments10.97M139.43M184.8M196.55M235.82M
Net Receivables00000
Inventory00000
Other Current Assets04.19M4.41M6.29M6.98M
Total Current Assets240.52M210.46M212.6M262.25M288.47M
Property, Plant & Equipment (Net)2.41M14.25M12.01M2.92M9.07M
Goodwill00000
Intangible Assets00000
Long-term Investments43.39M22.42M27.34M0111.25M
Tax Assets03.18M2.68M02.11M
Other Non-current Assets12.32M49K61K8.97M98K
Total Non-current Assets58.12M39.9M42.09M11.89M122.54M
Total Assets298.64M250.36M254.69M274.14M411M
Account Payables1.89M1.32M944K1.55M3.82M
Short-term Debt02.66M2.75M03.33M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities4.8M6.09M10.23M7.65M13.26M
Total Current Liabilities15.15M15.39M20.46M24.85M20.42M
Long-term Debt00004.11M
Deferred Tax Liabilities03.18M2.68M02.11M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities10.52M006.17M(4.11M)
Total Non-current Liabilities10.52M12.62M10.14M6.17M6.22M
Total Liabilities25.67M28.01M30.6M31.02M26.64M
Common Stock4K5K6K7K11K
Retained Earnings(245.11M)(334.23M)(434.93M)(562.77M)(692.24M)
Accumulated OCI(103K)(1.29M)258K379K786K
Other Stockholders Equity00000
Minority Interest00000
Total Equity272.98M222.35M224.09M243.12M384.36M
Total Debt1.93M12.1M10.21M3.18M11.55M
Net Debt(224.08M)(54.74M)(13.17M)(56.22M)(34.12M)

ORIC Pharmaceuticals, Inc.

NASDAQ:ORIC

Intrinsic Alpha fair value

Locked

Current Price

$7.65

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.